Page 1 of Clinical Trials for Drug E3810, 22 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
Study of E3810 for Healthy Japanese Male (Under Fasting Condition)
Last Updated: September 13, 2010
Condition(s): Healthy
2
Recruiting
Study of Oral E-3810, a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Last Updated: January 25, 2011
Condition(s): Solid Tumors
3
Completed
A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)
Last Updated: September 21, 2010
Condition(s): Healthy
4
Completed
A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets
Last Updated: November 4, 2010
Condition(s): Healthy
5
Recruiting
Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Last Updated: October 17, 2011
Condition(s): Gastric Ulcers; Duodenal Ulcers
6
Not yet recruiting
Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
Last Updated: October 17, 2011
Condition(s): Gastric Ulcers; Duodenal Ulcers
7
Completed
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
Last Updated: July 14, 2011
Condition(s): Non-erosive Gastroesophageal Reflux Disease
8
Completed
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
Last Updated: April 16, 2012
Condition(s): Refractory Reflux Esophagitis
9
Active, not recruiting
A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study:Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia )
Last Updated: August 24, 2011
Condition(s): Functional Dyspepsia
10
Completed
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
Last Updated: September 6, 2011
Condition(s): Non-erosive Gastroesophageal Reflux Disease
11
Completed
Clinical Pharmacology Study of 5 mg , 10 mg, 20 mg and 40 mg Tablets of E3810 in Healthy Adult Japanese Male
Last Updated: March 29, 2011
Condition(s): Healthy
12
Completed
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
Last Updated: November 4, 2009
Condition(s): Heartburn
13
Completed
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
Last Updated: March 30, 2010
Condition(s): Heartburn
14
Completed
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
Last Updated: March 17, 2010
Condition(s): Symptomatic Gastroesophageal Reflux Disease (sGERD)
15
Completed
A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms
Last Updated: January 28, 2011
Condition(s): Frequent Heartburn
16
Completed
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
Last Updated: November 2, 2009
Condition(s): Gastroesophageal Reflux Disease
17
Completed
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Last Updated: March 24, 2010
Condition(s): Gastroesophageal Reflux Disease (GERD)
18
Completed
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
Last Updated: March 17, 2010
Condition(s): Gastroesophageal Reflux Disease (GERD)
19
Completed
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Last Updated: March 10, 2010
Condition(s): Gastroesophageal Reflux Disease (GERD)
20
Completed
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Last Updated: March 10, 2010
Condition(s): Gastroesophageal Reflux Disease (GERD)

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Drug+E3810

Page 1 of Clinical Trials for Drug E3810, 22 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About